# Joyce O’Shaughnessy

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joyce-o-shaughnessy/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,284 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 62 |
| i10-index | 163 |
| Last Known Institution | Baylor University |
| OpenAlex ID | https://openalex.org/A5041912334 |
| ORCID iD | 0000-0002-2955-5523 |
| Works | 453 |

## Researcher papers

Showing 12 of 14.

- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer](https://scholariq.org/papers/phase-iii-trial-of-nanoparticle-albumin-bound-paclitaxel-compared-with/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-hziy-in-refractory-metastatic-triple-negative-breast/)
- [Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/iniparib-plus-chemotherapy-in-metastatic-triple-negative-breast-cancer/)
- [Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study](https://scholariq.org/papers/pembrolizumab-monotherapy-for-previously-treated-metastatic-triple-negative/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer](https://scholariq.org/papers/ductal-lavage-for-detection-of-cellular-atypia-in-women-at-high-risk-for-breast/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Baylor University](https://scholariq.org/institutions/baylor-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.